Letters To The Editor
Copyright ©2012 Baishideng. All rights reserved.
World J Clin Oncol. Aug 10, 2012; 3(8): 126-127
Published online Aug 10, 2012. doi: 10.5306/wjco.v3.i8.126
CD26: A prognostic marker of other systemic malignancies besides colo-rectal carcinomas
Shailendra Kapoor
Shailendra Kapoor, Private practice, 7487 Sherwood Crossing place # 302, Mechanicsville, VA 23111, United States
Author contributions: Kapoor S soley contributed to the manuscript.
Correspondence to: Shailendra Kapoor, MD, Private Practice, 7487 Sherwood Crossing Place # 302, 2400 Cary street, Mechanicsville, VA 23111, United States. shailendrakapoor@yahoo.com
Telephone: +1-867-7896789 Fax: +1-867-5676781
Received: April 4, 2012
Revised: July 21, 2012
Accepted: August 2, 2012
Published online: August 10, 2012

I read with great interest the recent article by Cordero et al in a recent issue of your esteemed journal. Interestingly, the past few years have seen the emergence of CD26 as an important diagnostic and prognostic marker for a number of systemic malignancies besides colo-rectal carcinomas. For instance, serum CD26 levels are an important emerging marker of B-cell chronic lymphocytic leukemia (B-CLL). In fact, Molica et al have recently reported shorter time to first treatment in B-CLL which exhibit higher serum CD26 levels and simultaneously demonstrate absence of mutation in IgV (H). Similarly, CD26 serves as a marker of poor prognosis in T cell lymphomas. Simultaneously, a poor response to 2’-deoxycoformycin is seen T cell lymphomas expressing CD26. Similarly, breast carcinomas exhibit decreased CD26 mean fluorescence intensity and a decreased percentage of CD26 positive lymphocytes in comparison to benign breast tumors and healthy individuals.

Keywords: CD26, Cancer, Carcinogenesis, Colon cancer, Marker